Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Couple wonders why vaccine is covered at a clinic, but not at a pharmacy ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental shingles vaccine Z-1018 caused an immune response comparable to that of GSK’s ...